Article thumbnail

Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12R beta(2) or IL-18R alpha

By ?????????

Abstract

The oncolytic adenovirus (Ad) is currently being advanced as a promising antitumor remedy as it selectively replicates in tumor cells and can transfer and amplify therapeutic genes. Interleukin (IL)-12 induces a potent antitumor effect by promoting natural killer (NK) cell and cytotoxic T cell activities. IL-18 also augments cytotoxicity of NK cells and proliferation of T cells. This effect further enhances the function of IL-12 in a synergistic manner. Therefore, we investigated for the first time an effective cancer immunogene therapy of syngeneic tumors via intratumoral administration of oncolytic Ad co-expressing IL-12 and IL-18, RdB/IL-12/IL-18. Intratumoral administration of RdB/IL-12/IL-18 improved antitumor effects, as well as increased survival, in B16-F10 murine melanoma model. The ratio of T-helper type 1/2 cytokine as well as the levels of IL-12, IL-18, interferon-gamma and granulocyte-macrophage colony-stimulating factor was markedly elevated in RdB/IL-12/IL-18-treated tumors. Mice injected with RdB/IL-12/IL-18 also showed enhanced cytotoxicity of tumor-specific immune cells. Consistent with these results, immense necrosis and infiltration of NK cells, as well as CD4(+) and CD8(+) T cells, were observed in RdB/IL-12/IL-18-treated tumor tissues. Importantly, tumors treated with RdB/IL-12/IL-18 showed an elevated number of T cells expressing IL-12R beta 2 or IL-18R alpha. These results provide a new insight into therapeutic mechanisms of IL-12 plus IL-18 and provide a potential clinical cancer immunotherapeutic agent for improved antitumor immunity.This work was supported by grants from the Ministry of Knowledge Economy (10030051, Dr C-O Yun), the Korea Science and Engineering Foundation (R15-2004-024-02001-0, 2009K001644, 2010-0029220, Dr C-O Yun), the Korea Food and Drug Administration (KFDA-10172-332 to Dr C-O Yun), and Yonsei University College of Medicine faculty research grant (6-2010-0052, Dr C-O Yun). I-K Choi is a graduate student sponsored by KOSEF through National Core Research Center for Nanomedical Technology. J-S Lee and S-N Zhang are graduate students sponsored by the Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea

Topics: cancer immunogene therapy, IL-12, IL-18, oncolytic adenovirus, T cells expressing IL-12Rβ2 or IL-18Rα
Publisher: NATURE PUBLISHING GROUP
Year: 2011
DOI identifier: 10.1038/gt.2011.37
OAI identifier: oai:repository.hanyang.ac.kr:20.500.11754/37851
Provided by: HANYANG Repository
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://hdl.handle.net/20.500.1... (external link)
  • https://www.nature.com/article... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.